

**IN THE UNITED STATES DESIGNATED/ELECTED OFFICE**

In re PATENT Application of

Tohru NATSUME et al.

Application No. 10/581,969

International Application No. PCT/JP2004/018179

International Filing Date: 7 December 2004

Confirmation No. 8384

For: NOVEL INTERACTION BETWEEN PROTEINS, AND THERAPEUTIC AGENT  
FOR DISUSE MUSCULAR ATROPHY OR METHOD ASSOCIATED WITH  
DISUSE MUSCULAR ATROPHY TAKING ADVANTAGE OF NOVEL  
INTERACTION

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98(a)(2), copies of the non patent literature cited are enclosed.

It is requested that the accompanying information disclosure statement be considered and made of record in the above-captioned application. To assist the Examiner, the documents are listed on the attached Form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

Date: April 26, 2007

  
Stanislaus Aksman  
Registration No. 28,562

Customer No. 25570

Roberts Mlotkowski & Hobbes P.C.  
P.O. Box 10064  
McLean, VA 22102  
Telephone: (703) 677-3003

the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/581,969	
			Filing Date		
			First Named Inventor	Tohru NATSUME	
			Group Art Unit		
Examiner Name					
Sheet	2	of	2	Attorney Docket Number	039371-17

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		KEIJI TANAKA, "Magic of ubiquitin that sends out new troops", <i>Experimental Medicine</i> , February 2003, Vol. 21, No. 3, pp. 330-339.	Partial
		MARCELO D. GOMES et al., "Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy", <i>Proc. Natl. Acad. Sci.</i> , December 4, 2001, Vol. 98, No. 25, pp. 14440-14445.	
		SUE C. BODINE et al., "Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy", <i>Science</i> , November 23, 2001, Vol. 294, pp. 1704-1708.	
		D.A. SCOTT et al., "Identification and mutation analysis of a cochlear-expressed, zinc finger protein gene at the DFNB7/11 and <i>dn</i> hearing-loss-loci on human chromosome 9q and mouse chromosome 19", <i>Gene</i> , 215 (1998), pp.461-469.	
		WEI DUAN et al., "Cloning and characterization of AWP1, a novel protein that associates with serine/threonine kinase PRK1 in vivo", <i>Gene</i> , 256 (2000), pp. 113-121.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.